diabetestalk.net

Reduced Sugar In Soft Drinks Would Prevent Diabetes, Study Says

Reduced sugar in soft drinks would prevent diabetes, study says

Reduced sugar in soft drinks would prevent diabetes, study says

Reducing the amount of sugar in soft drinks and fruit juices by 40% over five years could prevent 300,000 cases of diabetes in the UK and stop 1.5 million people from being overweight or obese, according to a study.
The report, immediately welcomed by Public Health England as a particular route to curbing excess weight in young people, is based on efforts to reduce salt content in many foods, which has already seen the amount used cut by a similar amount over the same time period.
Published in the journal Lancet Diabetes and Endocrinology, the study used data from both the government’s national diet and nutrition survey and the British Soft Drinks Association (BSDA) to calculate the consumption of so-called sugar-sweetened beverages, and how much they contribute to UK-wide sugar and energy intakes.
The authors, Prof Graham MacGregor and fellow academics at Queen Mary University of London, then estimated how much a person’s energy intake would fall through the hypothetical drop in sugar content, and the resultant reduction in body weight.
The report calculated that the 40% drop in sugar over five years would, by the end of the final year, see an average drop in adult body weight of 1.2kg, meaning about 500,000 adults would no longer be overweight and a million would not be obese.
This in turn would prevent between 274,000 and 309,000 cases of obesity-related type 2 diabetes over the next 20 years, the report concluded.
If fruit juices were excluded from the scheme, the study said, it could still prevent up to 250,000 cases of diabetes over the same period, with an averag Continue reading

Rate this article
Total 1 ratings
7 Diabetes Technology Updates for 2018

7 Diabetes Technology Updates for 2018

As I gathered my notes and thoughts about the potential of diabetes technology in 2018, I kept coming back to the running list of caveats and elephants in the room. Access and affordability have been headline-generating conversations across the diabetes community this year. On one hand, it feels a little weird to talk about crazy-advanced technology that will hopefully make its way to the diabetes community next year while we’re still trying to figure out why live-sustaining medication costs as much as it does. If you are struggling to afford insulin, do you have room to get excited about automated insulin delivery?
But, innovation is important.
The clinical trials and resources spent developing better, smarter, faster tools are essential to the grander conversation about improving the lives of people with diabetes. This shouldn’t ignore the Very Real issues that are being discussed, so I’m going to propose we try to walk and chew gum at the same time. Yes, I want better technology to help manage my diabetes. Yes, it should be affordable so that no one is priced out of quality diabetes care.
When I think about the scope and potential of diabetes technology, it’s more than just a specific product or products that may come to market. So here’s a glimpse at some of the companies and movements that I am going to pay close attention to next year as diabetes technology looks to take another major step forward in 2018.
Tandem’s PLGS Algorithm
PLGS, or Predictive Low Glucose Suspend, Tandem’s algorithm that will predict and prevent hypoglycemia events is coming next y Continue reading

Gut molecule that blocks ‘hunger hormone’ may spur new treatments for diabetes, anorexia

Gut molecule that blocks ‘hunger hormone’ may spur new treatments for diabetes, anorexia

Scientists once had high hopes that inhibiting a hormone named ghrelin would be the key to preventing obesity. Ghrelin didn’t turn out to be a weight loss panacea. But now, the discovery of the first molecule naturally made by the body that blocks ghrelin’s effects may open up new avenues for treating other conditions, including diabetes and anorexia. The finding may also explain some of the benefits of bariatric surgery, which shrinks or reroutes the stomach to control weight.
“It’s a very impressive piece of research,” says bariatric physician Carel le Roux of University College Dublin, who wasn’t connected to the study. “I think it will have significant clinical impact.”
When researchers discovered ghrelin about 20 years ago, they dubbed it the “hunger hormone” because early results suggested it ramped up our appetite. But studies soon found that thwarting the molecule didn’t curtail food consumption or promote weight loss in mice. Still, the hormone induces a variety of other positive changes in our metabolism. For example, ghrelin may bolster muscle strength, spurring scientists to test whether drugs that mimic the hormone can counteract the muscle deterioration and weakness often suffered by cancer patients.
Get more great content like this delivered right to you!
By signing up, you agree to share your email address with the publication. Information provided here is subject to Science's privacy policy.
The new study didn’t start as a hunt for ghrelin-blocking compounds. Instead, a team headed by researchers at NGM Biopharmaceuticals in South Sa Continue reading

Fitbit shares close up 10% on diabetes-monitoring partnership in new smartwatch

Fitbit shares close up 10% on diabetes-monitoring partnership in new smartwatch

Fitbit Inc.
Fitbit Inc. shares rallied Thursday to close at levels not seen since late January after the fitness-tracker company announced a collaboration with glucose-monitoring device company DexCom Inc. to allow diabetics to monitor their blood sugar through Fitbit’s new smartwatch.
Fitbit FIT, -1.34% shares surged to finish up 9.8% at $6.49, on more than double their 52-week average daily volume. Thursday marked the stock’s highest close since Jan. 27, after which the shares tumbled on disappointing holiday sales and a reduced outlook. Shares reached on intraday high of $6.78 in Thursday trading. Even with the jump, shares are still down 11% for the year while the S&P 500 index SPX, +0.70% has gained 10%.
DexCom DXCM, +1.93% shares, however, closed down 5.2% at $71.23, but are still up 19% for the year.
Under the collaboration, Fitbit plans to make data from DexCom’s continuous glucose monitors available on its first smartwatch offering, the Ionic. Fitbit said they hope to have the feature available in 2018.
In a statement, Fitbit said the collaboration would allow it and Dexcom “to develop and market products to help people better manage their diabetes and get a more complete picture of their overall health with easy-to-use mobile tools.”
“While we see this as an interesting strategic relationship that could help uptake in 2018, key to the stock will be market acceptance of the Ionic amidst a crowded competitive field this holiday season,” said Stifel analyst Jim Duffy in a note Thursday. Duffy has a “hold” rating on Fitbit with a target price of $6.
Continue reading

London trial to aggressively treat diabetes expanding

London trial to aggressively treat diabetes expanding

Aggressive treatment for Londoners with Type 2 diabetes has proven so popular, Lawson Health Research Institute will open up enrolment in a study for a third time since 2015.
Doctors usually start treating diabetics with a single medication, and only add other drugs and insulin if the disease worsens. That wait-and-see approach has been turned on its head in a study in which doctors treat patients aggressively from the start with two diabetes medications plus insulin at bedtime for three months.
“The goal of the . . . study is to take a proactive approach to help people early in the disease, normalize their blood sugars for a period of 12 weeks and then slow the progression of the disease and the need for additional medications,” says Dr. Irene Hramiak, Lawson researcher, endocrinologist and chief of the Centre for Diabetes, Endocrinology and Metabolism at St. Joseph’s Health Care London.
“We want to know if we can induce remission, for how long and whether it matters what combination of medications we use.”
Lawson is one of seven Canadian sites taking part in the REMIT study, led by the Population Health Research Institute, a joint institute of McMaster University and Hamilton Health Sciences. A preliminary study produced remission in up to 40 per cent of patients for at least three months.
With a family history of Type 2 diabetes, Greg Ackland was diagnosed more than six years ago when he underwent an operation for a hernia. He developed a mild infection and, while being treated, his care team discovered his blood sugar levels were high.
Ackland started treatmen Continue reading

No more pages to load

Popular Articles

Related Articles